RxDoctor Payments DataLook up a doctor →

Richard Rothschild, MD

Cardiovascular Disease · Oxnard, CANPI 1700847126

Payments from drug & device makers

$887,353in general payments, 2019–2025

Across 929 payments — averaging $955.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$819K
  • Cvrx, Inc.$22K
  • AstraZeneca$19K
  • Novartis$9K
  • Abiomed$4K
  • Acist Medical Systems, Inc.$2K
  • plus $13K from 40 others

What the payments were for

  • Speaking & faculty fees$23,55048%
  • Travel & lodging$3,4387%
  • Food & beverage$21,58844%
  • Education$3421%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$887,353 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$2,026,467
Medicare patients
716
Services billed
26,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$240,115
XareltoRivaroxaban180$234,115
Repatha SureclickEvolocumab153$151,814
EntrestoSacubitril/Valsartan87$102,218
FarxigaDapagliflozin Propanediol55$83,701
BrilintaTicagrelor63$46,314
Praluent PenAlirocumab50$33,138
JardianceEmpagliflozin30$31,737
VascepaIcosapent Ethyl35$25,201
Nebivolol Hcl231$17,217
OzempicSemaglutide17$16,150
Icosapent Ethyl36$7,554
Valsartan236$7,270
Rosuvastatin Calcium398$6,643
Metoprolol Succinate401$5,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$616$240,115203 claims
Johnson & JohnsonXarelto$928$234,115180 claims
AstraZenecaFarxiga, Brilinta$18,505$130,015118 claims
NovartisEntresto$9,317$102,21887 claims
Boehringer IngelheimJardiance$375$31,73730 claims
Novo NordiskOzempic$186$16,15017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →